NEW YORK — Christine Dusek has left her job as head of Ruder Finn’s US crisis and reputation risk management practice to head global communications for pharmaceutical company Mylan, maker of the EpiPen.

Dusek assumed the role earlier this month, capping roughly 3½ years in her executive VP role at Ruder Finn.  Dusek had been at Ruder Finn earlier in her career as well, serving as corporate reputation practice head for seven years ending in 2007.  She was IMS Health's global head of corporate communications for four years between her two Ruder Finn stints.

Laura Ryan, an executive VP who joined Ruder Finn from Cohn & Wolfe earlier this month, will assume Dusek’s responsibilities, the agency said.

In moving to Mylan, Dusek joins a company that is no stranger to crisis, nor the reputational damage, in which she specializes; In 2016, the company sparked high-profile wrath (and got hit with a subsequent $465m settlement) after raising EpiPen prices by roughly 400% between 2010 and 2016, rendering them unaffordable for many of the severe allergy sufferers they help.

Dusek also joins a small but growing list of marketing execs leaving agency life this month for in-house jobs.  In the last two weeks, Ketchum’s Paul Wood and Burson-Marsteller’s Alan Sexton announced their departures.